It would be a battle between the health insurance companies (that are equally as profit-oriented) and the hospital-pharmas. IMO Phase III approval of Nicosan would likely catapult it to become the #1 drug of choice. With so much publicity gathering steam on keeping the cost of health care down, this Infant Drug should accomplish its full potential in due time. Once the milestone is crossed, the world-wide use of Nicosan will become a standard protocol of treatment for SCD.
By the way, the dot-triple-zero XeChem would be remembered fondly as a very very inexpensive stock!
News 
Market Data 
Discover 
AI
